
    
      A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547
      monotherapy versus paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal
      Junction Cancer with FGFR2 Polysomy or Gene Amplification (SHINE study). Patients were to be
      assigned to strata by FGFR2 status of: polysomy, low or high gene amplification.
    
  